EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieBeobachtungsstudie

Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure

Francesco Bendandi, Tullio Palmerini, Federico De Marco, Cosmo Godino, Chiara Fraccaro, Marco Barbanti, Matteo Biroli, Carlo Gaspardone, Caterina Gandolfo, Gianmarco Annibali, Giuliano Costa, Andrea Rubboli und 12 weitere

JACC: Cardiovascular Interventions · 2025-11 · 18 (22) · 2728-2739

DOI: 10.1016/j.jcin.2025.09.018 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-11. Verfasst von Francesco Bendandi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Cardiology Unit, Ospedale Umberto I, Lugo, Italy. Electronic add…. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Transcatheter Aortic Valve Replacement, Bioprosthesis, Heart Valve Prosthesis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Single antiplatelet therapy (SAPT) is the standard treatment after transcatheter aortic valve replacement (TAVR). However, valve-in-valve TAVR to treat surgical bioprosthesis dysfunction carries an increased thrombotic risk and may benefit from more intensive antithrombotic treatment. OBJECTIVES: The aim of this study was to compare the outcomes of patients treated with dual antiplatelet therapy (DAPT) or SAPT in the first year after valve-in-valve TAVR. METHODS: Patients treated with valve-in-valve TAVR at 10 participating centers were included and grouped according to treatment with DAPT or SAPT, while those treated with oral anticoagulant therapy were excluded. Both clinical and echocardiographic outcomes were analyzed at 1-year follow-up. A propensity score was developed, then inverse probability of treatment weighting was applied in HR estimation to account for confounders. RESULTS: A total of 278 patients were included. No differences between groups were observed for major adverse cardiac and cerebrovascular events (HR: 0.499, 95% CI: 0.182-1.371; P = 0.178), major bleeding (HR: 0.776; 95% CI: 0.172-3.504; P = 0.741), and death (HR: 0.907; 95% CI: 0.272-3.022; P = 0.874). Fewer strokes were observed in patients treated with DAPT (HR: 0.093; 95% CI: 0.010-0.831; P = 0.033). Additionally, there was no significant difference in moderate or severe structural valve deterioration (1.9% vs 6.0%; P = 0.161). CONCLUSIONS: DAPT after valve-in-valve TAVR may be associated with a lower 1-year incidence of stroke, whereas no significant difference was observed for other major ischemic and bleeding outcomes or for premature valve deterioration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsTranscatheter Aortic Valve ReplacementBioprosthesisHeart Valve ProsthesisDual Anti-Platelet TherapyAortic ValveProsthesis FailureThrombosisAortic Valve StenosisHumansMaleFemaleTime FactorsRisk FactorsAged, 80 and overTreatment OutcomeAgedRisk AssessmentHemorrhageProsthesis DesignRetrospective StudiesDrug Administration Schedule

Stichwörter der Autor:innen

antithrombotic treatmentbleedingstrokevalve deteriorationvalve thrombosisvalve-in-valve TAVR

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Cardiology Unit, Ospedale Umberto I, Lugo, Italy. Electronic address: francesco.saia@unibo.it.
  • Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Structural and Valvular Interventional Cardiology Unit, IRCCS Centro Cardiologico Monzino, Milan, Italy.
  • Cardiology Unit, Heart Valve Center, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Cardiac, Thoracic and Vascular Sciences, Azienda Ospedale-Università Padova, Padova, Italy.
  • Cardiology Unit, Ospedale Umberto I, Università degli Studi di Enna "Kore," Enna, Italy.

Zitieren

APA

Bendandi, F., Palmerini, T., De Marco, F., Godino, C., Fraccaro, C., Barbanti, M., Biroli, M., Gaspardone, C., Gandolfo, C., Annibali, G., Costa, G., Rubboli, A., Tarantino, F. F., Moretti, C., Cavazza, C., Compagnone, M., Gennari, M., Cannata, S., Zimarino, M., …, & Saia, F. (2025). Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure. JACC: Cardiovascular Interventions, 18(22), 2728-2739. https://doi.org/10.1016/j.jcin.2025.09.018

Vancouver

Bendandi F, Palmerini T, De Marco F, Godino C, Fraccaro C, Barbanti M, et al. Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure. JACC: Cardiovascular Interventions. 2025;18(22):2728-2739. doi:10.1016/j.jcin.2025.09.018

BibTeX
@article{Bendandi2025,
  author = {Bendandi, Francesco and Palmerini, Tullio and De Marco, Federico and Godino, Cosmo and Fraccaro, Chiara and Barbanti, Marco and Biroli, Matteo and Gaspardone, Carlo and Gandolfo, Caterina and Annibali, Gianmarco and Costa, Giuliano and Rubboli, Andrea and Tarantino, Fabio F and Moretti, Carolina and Cavazza, Caterina and Compagnone, Miriam and Gennari, Marco and Cannata, Stefano and Zimarino, Marco and Musumeci, Giuseppe and Tarantini, Giuseppe and Taglieri, Nevio and Maisano, Francesco and Saia, Francesco},
  title = {Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {22},
  pages = {2728--2739},
  doi = {10.1016/j.jcin.2025.09.018}
}
Kostenlos starten →